ANGEL GUAN: Open Payments
NPI 1346813847 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,917 in 62 payments from 10 companies in 2025. Trend: 2023 $1,381 · 2024 $1,553 · 2025 $2,917
Food & beverage: $2,917
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 28 | $1,346 |
| Mirum Pharmaceuticals, Inc. | 6 | $545 |
| Gilead Sciences, Inc. | 6 | $370 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $252 |
| Intercept Pharmaceuticals, Inc. | 1 | $150 |
| Amgen Inc. | 1 | $122 |
| ABBVIE INC. | 2 | $48 |
| Invivyd Inc | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
Products named: REZDIFFRA, Livmarli, Livdelzi, XIFAXAN, OCALIVA, MAVYRET, PEMGARDA, IQIRVO.
Industry payments across NY — which companies pay providers there.
